This intracerebroventricular delivery of siRNA has been evaluated in a preclinical mouse model of Alzheimer’s disease, which showed that this amyloid precursor protein-targeting siRNA improved behavioral and physiological abnormalities [5]. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.